NDA 209387 · Exela Pharma
Nipride Rtu In Sodium Chloride 0.9%
Sodium Nitroprusside · Intravenous
Last checked: Nov 20, 2026Latest source record: Jul 13, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Mar 8, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
68
4 Phase 3, 9 recruiting
FAERS reports
387
360 serious, 85 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: (A) EXCESSIVE HYPOTENSION; (B) CYANIDE TOXICITY (A) EXCESSIVE HYPOTENSION: Sodium Nitroprusside can cause precipitous decreases in blood pressure which can lead to irreversible ischemic injuries or death. Use only with continuous blood pressure monitoring [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.1 ). (B) CYANIDE TOXICITY: Sodium nitroprusside metabolism produces dose-related cyanide, which can be lethal. A patient’s ability to buffer cyanide will be exceeded in less than one hour at the maximum dose rate (10 mcg/kg/min); limit infusions at the maximum rate to as short a duration as possible [see Warnings and Precautions ( 5.2 )]. WARNING: (A) EXCESSIVE HYPOTENSION; (B) CYANIDE TOXICITY (A) Sodium Nitroprusside can cause precipitous decreases in blood pressure which can lead to irreversible ischemic injuries or death. Use only with continuous blood...
What it is approved for
From the label in effect Jul 20, 2018.
Sodium nitroprusside is a direct acting vasodilator indicated for: • Immediate reduction of blood pressure ( 1.1 ) • Producing controlled hypotension to reduce bleeding during surgery. ( 1.2 ) • Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. ( 1.3 ) 1.1 Immediate Reduction of Blood Pressure Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. 1.2 Induction and Maintenance of Controlled Hypotension Sodium nitroprusside indicated for induction and maintenance of controlled hypotension in adults and children during surgery, to reduce bleeding. 1.3 Treatment of Acute Heart Failure Sodium nitroprusside is indicated for the treatment of acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- NIPRIDE RTU IN SODIUM CHLORIDE 0.9% · SODIUM NITROPRUSSIDE 20MG/100ML (0.2MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- NIPRIDE RTU IN SODIUM CHLORIDE 0.9% · SODIUM NITROPRUSSIDE 50MG/100ML (0.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- NIPRIDE RTU IN SODIUM CHLORIDE 0.9% · SODIUM NITROPRUSSIDE 10MG/50ML (0.2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Nitroprusside" as an intervention, any sponsor and status, largest first.
- Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED)Pivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT01422616 · 4,587 participants · Start Mar 2012 · Primary completion Aug 2018
Drug: Low-dose rtPA; Standard-dose rtPA · For: Ischemic Stroke; High Blood Pressure
Sites: Sydney, Australia
- Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMIPivotal-lookingStatus unknown
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT03406819 · 1,000 participants (planned) · Start Jan 7, 2018 · Primary completion Dec 31, 2018
Drug: Nitroprusside Sodium; Tirofiban Hydrochloride and 1 more · For: ST Segment Elevation Myocardial Infarction; Primary Percutaneous Coronary Intervention
Sites: Anyang, China; Jiaozuo, China; Jiyuan, China · 28 sites in all
- Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMIPivotal-lookingStatus unknown
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT03406832 · 1,000 participants (planned) · Start Jan 8, 2018 · Primary completion Jun 30, 2019
Drug: Nitroprusside Sodium; Tirofiban Hydrochloride and 1 more · For: ST Segment Elevation Myocardial Infarction; Elective Percutaneous Coronary Intervention
Sites: Anyang, China; Jiaozuo, China; Jiyuan, China · 28 sites in all
- Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093912 · 739 participants · Start Jun 2004 · Primary completion Oct 2006
Drug: clevidipine; sodium nitroprusside · For: Hypertension
Sites: Birmingham, Alabama; Montgomery, Alabama; Burbank, California · 29 sites in all
D. Walter WrayAcademic, hospital or other
NCT02966665 · 420 participants (planned) · Start Sep 2008 · Primary completion Aug 2030
Drug: BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate; BQ-123 and 3 more · For: Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure and 1 more
Sites: Salt Lake City, Utah
- Intensive Blood Pressure Reduction in Acute Cerebral HaemorrhagePivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT00226096 · 404 participants · Start Nov 2005 · Primary completion Sep 2007
Drug: Labetalol Hydrochloride; Metoprolol tartrate and 9 more · For: CVA (Cerebrovascular Accident); Cerebral Hemorrhage; Intracranial Hemorrhages
Sites: Concord, Australia; Gosford, Australia; Kogarah, Australia · 20 sites in all
- REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial InfarctionPivotal-lookingCompleted
University Hospitals, LeicesterAcademic, hospital or other
NCT01747174 · 247 participants · Start Oct 2011 · Primary completion Oct 2014
Drug: IC Adenosine; IC Sodium nitroprusside (SNP) · For: ST-elevation Myocardial Infarction (STEMI)
Sites: Leicester, United Kingdom; Newcastle upon Tyne, United Kingdom; Coventry, United Kingdom · 4 sites in all
- THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial InfarctionPivotal-lookingCompleted
Catholic University of the Sacred HeartAcademic, hospital or other
NCT00590070 · 240 participants · Start Jan 2008 · Primary completion Jun 2011
Drug: adenosine; nitroprusside and 1 more · For: Myocardial Infarction
Sites: Rome, Italy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- renal failure74
- pain62
- injury59
- anxiety58
- unevaluable event55
- drug ineffective53
- fear53
- toxicity to various agents49
- renal injury44
- emotional distress43
- anhedonia41
- renal impairment38
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 6 |
| 2006 | 10 |
| 2007 | 6 |
| 2008 | 6 |
| 2009 | 8 |
| 2010 | 10 |
| 2011 | 75 |
| 2012 | 9 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 16 |
| 2016 | 8 |
| 2017 | 15 |
| 2018 | 11 |
| 2019 | 20 |
| 2020 | 19 |
| 2021 | 29 |
| 2022 | 27 |
| 2023 | 27 |
| 2024 | 31 |
| 2025 | 19 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Repurposed antihypertensive drugs for negative symptoms in schizophrenia: A systematic review and meta-analysis.
Carnaval T, Bui M, Villoria J, et al. · Psychiatry Clin Neurosci 2025 · Systematic Review, Meta-Analysis
- The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients.
Aronson S, Dyke CM, Stierer KA, et al. · Anesth Analg 2008 · Comparative Study, Randomized Controlled Trial
- Acute hyperhomocysteinaemia affects pulse pressure but not microvascular vasodilator function.
Davis KR, Pearson H, Moat S, et al. · Br J Clin Pharmacol 2001 · Clinical Trial, Randomized Controlled Trial
- Sodium nitroprusside for advanced heart failure. A metanalysis of literature data.
Ghio S, Mandurino-Mirizzi A, La Rovere MT, et al. · Vascul Pharmacol 2023 · Meta-Analysis
- Sodium nitroprusside versus nicardipine for hypertension management after surgery: A systematic review and meta-analysis.
Villarreal EG, Flores S, Kriz C, et al. · J Card Surg 2020 · Comparative Study, Meta-Analysis
- Sodium nitroprusside: A comprehensive systematic review of its role across various clinical settings.
Recchioni T, Manzi G, Caputo A, et al. · Vascul Pharmacol 2026 · Systematic Review
Sponsor: Exela Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.